Title of article :
Impact of Nasopharyngeal FilmArray Respiratory Panel Results on Antimicrobial Decisions in Hospitalized Patients
Author/Authors :
Sakata, Kenneth K. Division of Pulmonary Medicine - Mayo Clinic, Phoenix, USA , Azadeh, Natalya Division of Pulmonary and Critical Care Medicine - Mayo Clinic, Rochester, USA , Brighton, Anjuli Division of Pulmonary Medicine - Mayo Clinic, Phoenix, USA , Temkit, Mhamed Division of Health Sciences and Research - Mayo Clinic Arizona, Scottsdale, USA , Klassen, Christine L. Division of General Internal Medicine - Mayo Clinic, Rochester, USA , Grys, Thomas E. Department of Laboratory Medicine and Pathology - Mayo Clinic, Phoenix, USA , Vikram, Holenarasipur R. Division of Infectious Diseases - Mayo Clinic, Phoenix, USA
Pages :
8
From page :
1
To page :
8
Abstract :
Objective. To determine whether results of the nasopharyngeal FilmArray respiratory panel (NP-FARP) influenced antibiotic decisions. Methods. We reviewed the medical records of nonintensive care unit (ICU) inpatients that had an NP-FARP performed at our institution between June 2013 and June 2014. +e inpatient records were reviewed 48 hours after the NP-FARP for the following data: demographic information; NP-FARP, serum procalcitonin, and methicillin-resistant Staphylococcus aureus nasal swab (MRSA NS) results; antibiotics prior and post-48 hours of the NP-FARP result; and the current immunosuppression status. Clinical outcome data were not obtained. Patients were categorized into those who had a positive (+) or a negative (−) NP-FARP. We further subdivided these two categories into groups A, B, and C based on the antibiotic modifications 48 hours after their NPFARP result. Group A included patients who were never initiated on antimicrobial therapy. Patients whose antibiotics were discontinued or deescalated were placed in group B. Patients with antibiotic escalation or continuation without change constituted group C. We compared and analyzed groups A, B, and C in the (+) and (−) NP-FARP cohorts. Results. A total of 545 patients were included. +ere were 143 (26%) patients with positive and 402 (74%) patients with negative NP-FARPs. Comparison of groups A, B, and C between those with a (+) and (−) NP-FARP were as follows: (+) A and (−) A, 28/143 (20%) and 84/402 (21%); (+) B and (−) B, 59/143 (41%) and 147/402 (37%); and (+) C and (−) C, 56/143 (39%) and 171/402 (43%), respectively. We found no statistically significant differences between groups (+) A versus (−) A, (+) B versus (−) B, and (+) C versus (−) C with respect to age, gender, MRSA NS result, procalcitonin result, or concurrent immunosuppression. Conclusion. In non-ICU inpatients, NP-FARP alone or in combination with procalcitonin or MRSA NS did not influence antibiotic decisions during the study period.
Keywords :
Nasopharyngeal , Respiratory Panel , Antimicrobial , Hospitalized Patients
Journal title :
Canadian Respiratory Journal
Serial Year :
2018
Full Text URL :
Record number :
2605621
Link To Document :
بازگشت